Cargando…
A(3) Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma
Human malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor of the serosal cavities whose 5-year survival rate is 15%. At present, there are no effective therapies for MPM. Although recent findings suggest that A(3) adenosine (A(3)AR) and P2X7 (P2X7R) receptors can be employed as anti...
Autores principales: | Vincenzi, Fabrizio, Rotondo, John Charles, Pasquini, Silvia, Di Virgilio, Francesco, Varani, Katia, Tognon, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518529/ https://www.ncbi.nlm.nih.gov/pubmed/34660262 http://dx.doi.org/10.3389/fonc.2021.679285 |
Ejemplares similares
-
Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain
por: Vincenzi, Fabrizio, et al.
Publicado: (2020) -
Pharmacology of Adenosine Receptors: Recent Advancements
por: Vincenzi, Fabrizio, et al.
Publicado: (2023) -
Adenosine and Inflammation: Here, There and Everywhere
por: Pasquini, Silvia, et al.
Publicado: (2021) -
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
por: Rossini, Marika, et al.
Publicado: (2018) -
Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications
por: Pasquini, Silvia, et al.
Publicado: (2022)